Latest News

STAT Plus: Can a small drug maker make amends with the FDA after giving its inspectors the bum’s rush?

Sometimes, small companies can give regulators the biggest headaches.

Take Immunomedics (IMMU). Last August, executives at the aspiring drug maker locked horns with investigators from the Food and Drug Administration, who sought to examine records pertaining to a quality-control problem at a company facility, but were denied access to all of the records. Why? The company cited attorney-client privilege.

Continue to STAT Plus to read the full story…

Source link

Related posts

Nutritional Therapist Addresses Notion That Carbs Make People Fat


Tenet Announces Upsizing and Pricing of its $700 Million Private Offering of Senior Secured Notes


STAT Plus: Chilean minister pushes back against pharma move to pressure its pricing policies


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy